Lenz Therapeutics announces positive Phase 3 CLARITY study results for presbyopia treatment, LNZ100.

Lenz Therapeutics announced positive topline results from its Phase 3 CLARITY study of two investigational formulations of aceclidine, LNZ100 and LNZ101, for the treatment of presbyopia. LNZ100 achieved primary endpoints, demonstrating statistically significant three-lines or greater improvement in Best Corrected Distance Visual Acuity (BCDVA) at near without losing one-line or more in distance visual acuity. The company plans to submit a New Drug Application for LNZ100 in mid-2024.

Articles

Street Insider

Medscape

RTTNews

Market Screener

U.S. News Money

RTTNews

-- show less --

Further Reading

Related Stories